Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.gastrohep.2014.05.009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
AGA Clinical Practice Update on Screening and Surveillance in Individuals at Increased Risk for Gastric Cancer in the United States: Expert Review.
Gastroenterology
December 2024
Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Palo Alto, California.
Description: Gastric cancer (GC) is a leading cause of preventable cancer and mortality in certain US populations. The most impactful way to reduce GC mortality is via primary prevention, namely Helicobacter pylori eradication, and secondary prevention, namely endoscopic screening and surveillance of precancerous conditions, such as gastric intestinal metaplasia (GIM). An emerging body of evidence supports the possible impact of these strategies on GC incidence and mortality in identifiable high-risk populations in the United States.
View Article and Find Full Text PDFSkin as a Reflection of Gut Health: An Overview of Dermatological Manifestations in Primary Neoplastic and Autoimmune Gastrointestinal Disorders.
Cureus
October 2024
Internal Medicine, Jinnah Postgraduate Medical Centre, Karachi, PAK.
Gastrointestinal (GI) diseases can present with several extraintestinal manifestations, and cutaneous signs and symptoms are most frequent. Although conventionally GI and skin are considered two entirely separate organ systems, they are closely correlated in origin. An increasing amount of data highlights the complex relationship between GI and dermatological conditions.
View Article and Find Full Text PDFCirculating Chromogranin A as a Surveillance Biomarker in Patients with Carcinoids-The CASPAR Study.
Clin Cancer Res
December 2024
Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Article Synopsis
- Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) can vary in aggressiveness, and this study aimed to confirm an automated test for serum chromogranin A (CgA) to help monitor these tumors' progression.
- The study involved 153 GEP-NET patients and assessed tumor progression using imaging alongside changes in CgA levels, with a specific threshold indicating tumor growth.
- Results showed the CgA test had high specificity (93.4%) and negative predictive value (84.3%), suggesting it could be a valuable tool alongside standard imaging methods for tracking GEP-NETs.
Biomarkers to Inform Prognosis and Treatment for Unresectable or Metastatic GEP-NENs.
JAMA Oncol
December 2024
University of Toronto, Toronto, Ontario, Canada.
Article Synopsis
- Evidence-based treatment for advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) requires personalized decisions that take into account individual patient and cancer characteristics. !* -
- A multidisciplinary panel reviewed 131 publications to develop a guidance document with 24 recommendations and 5 good clinical practice statements focusing on diagnostic features and biomarkers for managing unresectable or metastatic GEP-NENs. !* -
- The document emphasizes treatment strategies based on tumor characteristics and specific biomarkers, and it received endorsements from major neuroendocrine tumor organizations. !*
Comprehensive clinicopathologic features in autoimmune atrophic gastritis: Insights from a European cohort of 57 patients.
Pathol Res Pract
November 2024
Department of Pathology, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Context: Autoimmune atrophic gastritis (AAG) is a frequently underdiagnosed disease due to its broad-spectrum clinical presentation. The diagnosis is based on histological confirmation of corpus-restricted metaplastic chronic atrophic gastritis.
Objective: To thoroughly describe the histological features of a European cohort of AAG patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!